-

11:34:31 AM

PCSA Stock News

PCSA - Processa Pharmaceuticals Inc

10/12/21 8:30 AM

Nasdaq : PCSA

clinical trial

Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today

RHEA-AI

neutral

09/16/21 11:05 AM

Nasdaq : PCSA

conferences

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Update

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today

RHEA-AI

neutral

09/16/21 8:30 AM

Nasdaq : PCSA

conferences

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today

RHEA-AI

neutral

08/23/21 4:00 PM

Nasdaq : PCSA

conferences

Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, August 25-27

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition today announced it will present at the

RHEA-AI

neutral

08/12/21 5:15 PM

Nasdaq : PCSA

Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing drugs to improve the survival and/or quality of life

RHEA-AI

neutral

08/06/21 8:30 AM

Nasdaq : PCSA

Processa Pharmaceuticals Schedules Conference Call to Discuss Second Quarter Results and Provide Drug Development Update on August 12 at 5:30 p.m. EST

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a

RHEA-AI

neutral

08/04/21 8:30 AM

Nasdaq : PCSA

Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer

RHEA-AI

positive

07/27/21 8:30 AM

Nasdaq : PCSA

conferences

Processa Pharmaceuticals to Present at “Zooming with LD Micro” Virtual Investor Event on July 29, 2021 at 12:00 p.m. ET

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it will be presenting at the upcoming “Zooming with LD Micro” virtual investor event on Thursday, July 29th, 2021 at 12:00 PM ET. Investors and other individuals may access the

RHEA-AI

neutral

07/06/21 8:15 AM

Nasdaq : PCSA

conferences

Processa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that the company will present at Access to Giving Virtual Conference. The presentation will be given by Processa’s Chief Executive Officer, Dr. David Young. Registration Details Date:

RHEA-AI

neutral

06/17/21 9:15 AM

Nasdaq : PCSA

PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP) to license in RX-3117. RX-3117 is an oral, anticancer agent with an improved pharmacological

RHEA-AI

very positive

PCSA Data:

IndustryHeavy Duty Truck Manufacturing
Websiteprocessapharmaceuticals.com
Security nameProcessa Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code3531
Employees14
Tags
- Industrial Machinery
- Producer Manufacturing
- Manufacturing
- Heavy Duty Truck Manufacturing

PCSA Description:

Processa Pharmaceuticals, Inc. was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. The Company acquired the assets of Promet Therapeutics, LLC in October of 2017 and assembled a proven regulatory science development team, management team, and Board of Directors. The Processa drug development team members have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings. PCS-499 represents the first Processa drug that can potentially be used in several unmet medical need conditions.